ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct OfferingGlobeNewsWire • 06/12/24
ProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct OfferingGlobeNewsWire • 06/10/24
ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational UpdatesGlobeNewsWire • 06/10/24
ProKidney to Host Virtual KOL Event to Discuss Current Treatment Landscape of Chronic Kidney Disease Caused by Diabetes and Data from Phase 2 RMCL-002 Clinical Trial on May 28, 2024GlobeNewsWire • 05/21/24
ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical OperationsGlobeNewsWire • 03/25/24
ProKidney Reports Full Year 2023 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 03/21/24
Here's Why ProKidney Corp. (PROK) Is a Great 'Buy the Bottom' Stock NowZacks Investment Research • 12/13/23
ProKidney to Participate in a Fireside Chat at the Upcoming Evercore ISI 6th Annual HEALTHCONx ConferenceGlobeNewsWire • 11/21/23
After Plunging -37.39% in 4 Weeks, Here's Why the Trend Might Reverse for ProKidney Corp. (PROK)Zacks Investment Research • 11/16/23
ProKidney Announces Positive Interim Data from RMCL-002 Phase 2 Clinical Trial of Renal Autologous Cell Therapy (REACT®) for Diabetic CKD and Provides Corporate UpdatesGlobeNewsWire • 11/13/23
ProKidney Announces Four Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2023GlobeNewsWire • 10/30/23
ProKidney Corp. (PROK) Loses -54.93% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 10/17/23
ProKidney to Participate in Fireside Chat at the Morgan Stanley Global Healthcare ConferenceGlobeNewsWire • 09/05/23